About us

Technologies for Better Life

CrossLife Technologies is a life sciences company founded with the mission of alleviating suffering and improving health through the development and commercialization of innovative molecular diagnostics for infectious diseases and non-communicable diseases. We are focused on discovering, developing and commercializing innovative DNA/RNA based diagnostic technologies and products.

The company was formed in 2010 and the management team consists of experienced diagnostic kit & test development personnel. We are committed to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular diagnostics. We will achieve this by developing new technologies, complying with government regulations, maintaining an effective quality program, and utilizing customer feedback to improve our products and processes.

Mission Statement

“Saving Lives And Improving Health Through Life Technologies”

A Revolution in Low Cost Point-of-Care Diagnostics

Crosslife Technologies has developed a novel U.S. patent pending, point-of-care technology called TARA (Template-assisted Rapid Assay) to detect infectious pathogens directly from diverse sample types without sample preparation, polymerase chain reaction (PCR) or instrumentation.

We have filed a US patent on this technology (USPTO Application Number 15/068371).  This disruptive technology is being developed into pathogen detection tests for many infectious diseases including HIV, malaria, chikungunya, flu.

CrossLife has recently been awarded a Phase 1 Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH) to develop a rapid point-of-care detection test for the dengue, chikungunya, HIV, Influenza virus using this platform technology.